BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms

 BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms

Shots:

  • The P-Ib/II POC, RELEASE study involves assessing BXCL50 (130/ 60 /90 /120 /180 and 240 mcg, bid, ~ 12 hrs apart, 7 days treatment) vs PBO, following discontinuation of morphine maintenance in 125 patients with opioid use disorder who are physically dependent on opioids
  • The study met its 1EPs and 2EPs in multiple dose cohort demonstrated numerically improvement in retention rates, rate of retention in 120mcg and 180mcg showed 42% and 52% vs 24% @Day 6 and was well tolerated
  • The data from multiple dosing regimen has the potential to support the investigation across additional indications and treatment settings

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post